1D01
943
21941
ENSG00000120949
ENSMUSG00000028602
P28908
Q60846
NM_001243NM_001281430NM_152942
NM_009401
NP_001234NP_001268359
NP_033427
CD30, also known as TNFRSF8 (TNF receptor superfamily member 8),[5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker.
This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB.[6] It is a positive regulator of apoptosis,[7] and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.[citation needed] Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[5]
CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.[8] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.[9]
CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:
Brentuximab vedotin is also currently being studied in and recommended for treating:
CD30 has been shown to interact with TRAF5,[6] and TRAF2.[6][7]
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Lokasi Pengunjung: 52.15.199.109